Initial Results from a Phase II Study (TACTI-002) in Metastatic Non-Small Cell Lung or Head and Neck Carcinoma Patients Receiving Eftilagimod Alpha (Soluble Lag-3 Protein) and Pembrolizumab

被引：0
|
作者：
Doger, Berhard [1 ]
Majem, Margarita [2 ]
Felip, Eriqueta [3 ]
Carcereney, Enric [4 ]
Clay, Tim [5 ]
Triebel, Frederic [6 ]
机构：
[1] Fdn Jimenez Diaz, Madrid, Spain
[2] Hosp Santa Creu & Sant Pau, Barcelona, Spain
[3] Vall dHebron Univ Hosp, Barcelona, Spain
[4] Hosp Badalona Germans Trias & Pujol, Badalona, Spain
[5] St John God Subiaco Hosp, Subiaco, WA, Australia
[6] Immutep SAS, Paris, France
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2020年 / 43卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
997
引用
收藏
页码：213 / 214
页数：2
相关论文
共 50 条
  • [1] Initial results from a phase II study (TACTI-002) in metastatic non-small cell lung or head and neck carcinoma patients receiving eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab.
    Felip, Enriqueta
    Doger, Bernard
    Majem, Margarita
    Carcereny, Enric
    Krebs, Matthew
    Peguero, Julio Antonio
    Roxburgh, Patricia
    Forster, Martin
    Bajaj, Pawan
    Clay, Timothy Dudley
    Triebel, Frederic
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [2] Initial results from a Phase II study (TACTI-002) in non-small cell lung cancer, or head and neck cancer patients receiving eftilagimod alpha (LAG-3 fusion protein) and pembrolizumab
    Peguero, Julio
    Felip, Enriqueta
    Doger, Bernard
    Majem, Margarita
    Carcereny, Enric
    Clay, Tim
    Bajaj, Pawan
    Krebs, Matthew
    Triebel, Frederic
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [3] A PHASE II STUDY (TACTI-002) OF EFTILAGIMOD ALPHA (A SOLUBLE LAG-3 PROTEIN) WITH PEMBROLIZUMAB IN PD-L1 UNSELECTED PATIENTS WITH METASTATIC NON-SMALL CELL LUNG(NSCLC) OR HEAD AND NECK CARCINOMA(HNSCC)
    Krebs, Matthew
    Majem, Margarita
    Felip, Enriqueta
    Forster, Martin
    Doger, Bernard
    Clay, Tim
    Carcereny, Enric
    Peguero, Julio
    Horn, Leora
    Bajaj, Pawan
    Roxburgh, Patricia
    Brignone, Chrystelle
    Mueller, Christian
    Triebel, Frederic
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A472 - A473
  • [4] A multicenter, phase II study of soluble LAG-3 (Eftilagimod alpha) in combination with pembrolizumab (TACTI-002) in patients with advanced non-small cell lung cancer (NSCLC) or head and neck squamous cell carcinoma (HNSCC).
    Peguero, Julio Antonio
    Bajaj, Pawan
    Carcereny, Enric
    Clay, Timothy Dudley
    Doger, Bernard
    Felip, Enriqueta
    Krebs, Matthew
    Forster, Martin
    Aix, Santiago Ponce
    Roxburgh, Patricia
    Triebel, Frederic
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [5] Initial results from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected first-line metastatic non-small cell lung carcinoma
    Majem, M.
    Felip, E.
    Doger, B.
    Akay, M.
    Carcereny, E.
    Clay, T.
    Krebs, M. G.
    Peguero, J.
    Triebel, F.
    ANNALS OF ONCOLOGY, 2020, 31 : S818 - S818
  • [6] Initial results from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as 2nd line treatment for PD-L1 unselected metastatic head and neck cancer patients
    Forster, M.
    Felip, E.
    Doger, B.
    Lopez Pousa, A.
    Carcereny, E.
    Bajaj, P.
    Church, M.
    Peguero, J.
    Roxburgh, P.
    Triebel, F.
    ANNALS OF ONCOLOGY, 2020, 31 : S667 - S667
  • [7] A phase II study (TACTI-002) in first-line metastatic non-small cell lung carcinoma investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab: Updated results from a PD-L1 unselected population.
    Felip, Enriqueta
    Majem, Margarita
    Doger, Bernard
    Clay, Timothy Dudley
    Carcereny, Enric
    Bondarenko, Igor
    Peguero, Julio Antonio
    Cobo-Dols, Manuel
    Forster, Martin
    Ursol, Grygorii
    Ledo, Gema Garcia
    Vila, Laia
    Krebs, Matthew
    Iams, Wade Thomas
    Mueller, Christian
    Triebel, Frederic
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [8] Final results from TACTI-002 Part C: A phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with metastatic 2nd line head and neck squamous cell carcinoma unselected for PD-L1.
    Doger de Speville, Bernard
    Felip, Enriqueta
    Forster, Martin
    Majem, Margarita
    Bajaj, Pawan
    Peguero, Julio Antonio
    Carcereny, Enric
    Krebs, Matthew G.
    Mukherjee, Uma
    Mueller, Christian
    Triebel, Frederic
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [9] Combining the antigen-presenting cell activator eftilagimod alpha (soluble LAG-3) and pembrolizumab: Overall survival data from the first line non-small cell lung carcinoma (NSCLC) cohort of TACTI-002 (phase II)
    Carcereny, E.
    Felip, E.
    Majem, M.
    Doger de Speville, B.
    Clay, T. D.
    Bondarenko, I.
    Peguero, J.
    Dols, M. Cobo
    Forster, M. D.
    Ursol, G.
    Kalinka, E.
    Garcia Ledo, G. M.
    Vila Martinez, L.
    Iams, W.
    Krebs, M. G.
    Kefas, J.
    Efthymiadis, K.
    Perera, S.
    Mueller, C.
    Triebel, F.
    ANNALS OF ONCOLOGY, 2023, 34
  • [10] COMBINING THE ANTIGEN-PRESENTING CELL ACTIVATOR EFTILAGIMOD ALPHA (SOLUBLE LAG-3) AND PEMBROLIZUMAB: EFFICACY RESULTS FROM THE 1ST LINE NON-SMALL CELL LUNG CANCER COHORT OF TACTI-002 (PHASE II)
    Iams, Wade
    Felip, Enriqueta
    Majem, Margarita
    Doger, Bernard
    Clay, Tim
    Carcereny, Enric
    Bondarenko, Igor
    Peguero, Julio
    Cobo-Dols, Manuel
    Forster, Martin
    Ursol, Grygorii
    Kalinka, Ewa
    Ledo, Gema Garcia
    Martinez, Laia Vila
    Krebs, Matthew
    Balea, Begona Campos
    Kefas, Joanna
    Mueller, Christian
    Brignone, Chrystelle
    Triebel, Frederic
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A1529 - A1529
12345